Cytokinetics
CYTK
192 hedge funds and large institutions have $1.74B invested in Cytokinetics in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 62 increasing their positions, 63 reducing their positions, and 17 closing their positions.
88% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 17
65% more call options, than puts
Call options by funds: $5.35M | Put options by funds: $3.23M
15% more capital invested
Capital invested by funds: $1.51B → $1.74B (+$224M)
8% more funds holding
Funds holding: 178 → 192 (+14)
2.22% more ownership
Funds ownership: 103.03% → 105.26% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$33.1M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$14.9M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$14.3M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$101M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.9M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$12.8M |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$11.8M |
| 5 |
State Street
Boston,
Massachusetts
|
-$10.7M |
CYTK Hedge Fund Activity: Q1 2021 in Review
192 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2021, worth a combined $1.74B — up 15% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CYTK positions and 17 closed out — a net gain of 15 holders — while 62 added to existing stakes and 63 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $59.9M. The largest seller was BVF Inc, exiting entirely with an estimated $101M sold.
- 192 institutional investors held Cytokinetics (CYTK) as of Q1 2021, up from 178 in Q4 2020.
- Funds reported $1.74B of Cytokinetics stock for Q1 2021, up 15% quarter-over-quarter.
- 32 funds opened new Cytokinetics positions in Q1 2021 and 17 closed out, a net change of +15 holders.
- The largest Cytokinetics buyer in Q1 2021 was Fidelity Investments, an estimated $59.9M added.
- The largest Cytokinetics seller in Q1 2021 was BVF Inc, an estimated $101M sold.
Based on aggregated 13F filings for Q1 2021.